3 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Clinical safety, immunogenicity and efficacy of a therapeutic vaccine that combines peptides mimicking antigen receptors on autoimmune B and T cells associated with myasthenia gravis (Myasterix)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,
The MYASTERIX project will advance a therapeutic vaccine candidate (designated orphan drug) indicated for the autoimmune disease myasthenia gravis (MG) to clinical proof of concept studies. MG is caused by T cell dependent antibodies that bind to and deplete acetylcholine receptors (AChR) at neuromuscular junctions causing muscle weakness by interfering with neuromuscular transmission and junction ...
Voir le projet
6
Participants partenaires
TERMINÉ
BIOIMAGE-Neuromuscular Diseases (BIOIMAGE-NMD)
Date du début: 1 oct. 2013, Date de fin: 31 mars 2017,
BIOIMAGE-NMD will develop and apply imaging technology to monitor response to novel therapies in neuromuscular diseases (NMD) and will use Duchenne muscular dystrophy (DMD) as an exemplar disease. DMD is well characterised genetically and clinically but to date a disease modifying treatment is not available. One of the most promising developments for future treatment of NMD is RNA modulation throu ...
Voir le projet
9
Participants partenaires
TERMINÉ
Consortium for Products across Europe in Duchenne Muscular Dystrophy (SCOPE-DMD)
Date du début: 1 juin 2013, Date de fin: 31 mai 2016,
"This project builds on results from the TREAT-NMD and BIO-NMD European projects to develop a personalised-medicinal product through to market for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is an inheritable, childhood rare disease that affects approximately 1 in 3,500 newborn boys. This rare disease is caused by mutations in the dystrophin gene, resulting in the absence or defect of ...
Voir le projet